Who Paid My Doc
Defitelio
Drug Hematology/Oncology
NDC 68727-800-02
General payments
$2,418,790
Research payments
$10,834,072
Through program year 2025, $2,418,790 in general payments and $10,834,072 in research payments were reported against Defitelio (Hematology/Oncology).
No combined total These are different kinds of money, reported under different rules. A meal and a clinical trial grant do not add up to anything meaningful, so this site does not add them.
By program year
12 rows| Year | Kind | Amount | Payments |
|---|---|---|---|
| 2025 | General | $238,720 | 542 |
| 2025 | Research | $773,452 | 6 |
| 2024 | General | $430,281 | 720 |
| 2024 | Research | $337,490 | 2 |
| 2023 | General | $656,578 | 795 |
| 2023 | Research | $531,033 | 5 |
| 2022 | General | $309,896 | 605 |
| 2022 | Research | $4,211,608 | 27 |
| 2021 | General | $338,393 | 659 |
| 2021 | Research | $2,049,422 | 259 |
| 2020 | General | $444,922 | 202 |
| 2020 | Research | $2,931,067 | 456 |
Breakdown
The top 5 of the 100 largest recipients; each share is of general payments naming this product in 2025.
The top 5 of 28 specialties; each share is of general payments naming this product to practitioners with a specialty in 2025. Each practitioner is counted under their primary specialty.
The top 5 of 36 states; each share is of general payments naming this product in 2025 where a state was reported.
Records
3,523 general · 755 researchEvery payment, record by record
Date, amount, who was paid and what for — filter by year and kind, or download as CSV, free, in files of 5,000 rows.
What you are looking at
Manufacturers name the drug, biological or device a payment relates to. CMS does not give products their own identifiers, so a product here is assembled from how it was reported — a brand may appear under more than one spelling, and this page covers one of them rather than the brand as a whole.